SEATTLE – Real-world data on quality of life (QoL) and safety of selinexor in combination with bortezomib and dexamethasone (SVd) in patients with relapsed/refractory multiple myeloma (R/RMM) 25. Oktober 2024 Dechow T., Pelz H., Zaiss M., Wilop S., Nusch A., Schulz H., Von der Heyde E. Ringwald K., Kummer D., Woerner S.M., Marschner N., Marschner P.; 2024 Download First real-world insights into medical resource utilization in patients with Waldenström’s macroglobulinemia (WM) treated with zanubrutinib – results from the interim analysis 1 (IA1) of the ARIADNE study Greil R., Melchardt T., Dörfel S., von der Heyde E., Illmer T., Nusch A., Schulz C.-O., Janssen J., Schöttker B., Schwarzer A., Medinger T., Kummer… Weiterlesen Real-world data on patients’ adherence to prescribed treatment schedules with carfilzomib and dexamethasone (Kd), or in combination with lenalidomide (KRd) or daratumumab (KdD) in patients with multiple myeloma – Results from the interim analysis 3 of CARO Knauf, Wolfgang; Uhlig, Jens; Von der Heyde, Eyck; Losem, Christoph ; Ammon, Andreas; Nusch, Arnd; Schlag Rudolf; Schulz, Holger; Behlendorf, Timo; Siebenbach, Hans Ulrich; Serrer,… Weiterlesen